The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Christine Parkinson
No Relationships to Disclose
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Boryung; GI Innovation; Takeda
Research Funding - AstraZeneca; CKD pharm; Clovis Oncology; OncoQuest
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Arcus Biosciences; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; InxMed; Iovance Biotherapeutics; Janssen Oncology; Laekna Therapeutics; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; Novocure; Onconova Therapeutics; OncoQuest; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sutro Biopharma; Takeda; Tarveda Therapeutics; Tesaro; Toray Industries; Translational Genomics Research Institute; VBL Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Michelle K. Wilson
No Relationships to Disclose
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Genmab; Gradalis; Immunogen; Merck; Merck; Novocure; Oncolytics; OncoMed; OncXerna Therapeutics; Regeneron; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Immunogen (Inst); Johnson & Johnson; Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Domenica Lorusso
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Sharad A. Ghamande
Consulting or Advisory Role - Seagen
Speakers' Bureau - Eisai; Tesaro/GSK
Research Funding - Abbvie (Inst); Advaxis (Inst); Akeso Biopharma (Inst); Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ellipses Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Merck Serono (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst)
 
Athina Christopoulou
Honoraria - AstraZeneca Canada; GlaxoSmithKline; MSD; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Novartis; Pfizer
Research Funding - Clovis Oncology; Syneos Health
 
Emily Prendergast
Consulting or Advisory Role - GOG Foundation; HERON
 
Fuat Demirkiran
No Relationships to Disclose
 
Ramey D. Littell
No Relationships to Disclose
 
Anita M. Chudecka-Glaz
No Relationships to Disclose
 
Mark Aloysuis Morgan
No Relationships to Disclose
 
Sandra M. Goble
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Stephanie Hume
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Travel, Accommodations, Expenses - Clovis Oncology
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Zeria Pharmaceutical
Consulting or Advisory Role - Eisai; Genmab; MSD; NanoCarrier; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca Canada (Inst); Chugai Pharma (Inst); Eisai (Inst); Genmab (Inst); ImmunoGen (Inst); Kaken Pharmaceutical (Inst); Merck KGaA (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Seagen (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - MSD
 
Rebecca Kristeleit
Honoraria - AstraZeneca; Basilea Pharmaceutical; Clovis Oncology; GlaxoSmithKline; Incyte; Merck Sharp & Dohme; Roche/Genentech; Shattuck Labs; Tesaro
Consulting or Advisory Role - Basilea; Cerulean Pharma; Clovis Oncology; Roche/Genentech; Sotio
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; Valirx